Navigation Links
Ampio Pharmaceuticals Schedules 2012 Update Webcast
Date:5/14/2012

GREENWOOD VILLAGE, Colo., May 14, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion™, Optina™ and Zertane™), licensing distribution of those drugs and engaged in further drug development), will hold a webcast on Wednesday, May 16, 2012, at 4:15 p.m. EDT.  Management will outline the Company's 2012 progress, provide a detailed review for each of its three lead products and update the status of licensing and collaboration efforts.

Dial-in Information

United States:  800.295.3991
International:  617.614.3924

Passcode: 54743349

The call also can be accessed at www.ampiopharma.com

Replay Information

United States:  888 286.8010
International:  617 801.6888

Passcode: 29004533

The replay will be posted approximately two hours after the completion of the live event, and it will be available for 7 days.  Ampio will post a replay of the May 16, 2012 call on its website. 

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.

Contact
Investor Relations, 
Ampio Pharmaceuticals, Inc.
 720-437-6500


'/>"/>
SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
2. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
3. Ampio Strengthens Patent Protection for Lead Drug Ampion™
4. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
5. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
6. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
7. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
8. Executive Changes at Ampio
9. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
10. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
11. Ampio Responds to Recent Publications by Anonymous Short Sellers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017 MabVax ... oncology drug development company, announces that it has ... Administration (FDA) authorizing the initiation a Phase I ... for pancreatic cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is ... MabVax plans to initiate the phase I clinical ...
(Date:2/23/2017)... 23, 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) ... oncology and dermatology biopharmaceutical company, today announced that it ... Rodrigues as special advisers to the Company,s Board ... the board on financial and corporate strategy. ... commitment of up to $2.5 million from Eric ...
(Date:2/23/2017)... Feb. 22, 2017 Medical Imaging ... imaging is performed to reveal the internal structures hidden ... the medical condition. It plays a vital role not ... as it is taken into consideration during the follow-up ... X-rays, SPECT/PET, ultrasound, CT, and MRI. For the diagnosis ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... Current Meditation , a ... franchising throughout the U.S. starting this spring. Current Meditation focuses on “meditation for ... mainstream. Current Meditation will be the first meditation concept in the U.S. offering ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Center for Autism and ... for Autism Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. ... to see films in an environment that accommodates their unique needs. , Launched ...
(Date:2/23/2017)... ... February 23, 2017 , ... CALNOC, the nation’s first and only nursing ... upcoming conference – Empowerment, Value and Collaboration – in Seattle, WA on October 23, ... Virginia Mason Health System in Seattle since 2000. In addition to his role at ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/23/2017)... Australia (PRWEB) , ... February 23, 2017 , ... ... With perseverance and disciplined exercise regime, the author was able to successfully recover. In ... collates all relevant information for various sources on the principals of massage, anatomy ...
Breaking Medicine News(10 mins):